Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ASXL2-SRBD1

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ASXL2-SRBD1
	FusionPDB ID: 7318
	FusionGDB2.0 ID: 7318
		Hgene	Tgene
	Gene symbol	ASXL2	SRBD1
	Gene ID	55252	55133
	Gene name	ASXL transcriptional regulator 2	S1 RNA binding domain 1
	Synonyms	ASXH2\|SHAPNS	-
	Cytomap	2p23.3	2p21
	Type of gene	protein-coding	protein-coding
	Description	putative Polycomb group protein ASXL2additional sex combs like 2, transcriptional regulatoradditional sex combs-like protein 2polycomb group protein ASXH2	S1 RNA-binding domain-containing protein 1H_NH0576F01.1WUGSC:H_NH0576F01.1
	Modification date	20200313	20200313
	UniProtAcc	Q76L83 Main function of 5'-partner protein: FUNCTION: Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility (By similarity). Involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as peroxisome proliferator-activated receptor gamma (PPARG). Acts as coactivator for PPARG and enhances its adipocyte differentiation-inducing activity; the function seems to involve differential recruitment of acetylated and methylated histone H3. {ECO:0000250, ECO:0000269\|PubMed:21047783}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000435504, ENST00000272341, ENST00000336112, ENST00000404843, ENST00000497092,	ENST00000490133, ENST00000263736, ENST00000535761,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	18 X 11 X 10=1980	3 X 3 X 3=27
	# samples	24	4
	** MAII score	log2(24/1980*10)=-3.04439411935845 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(4/27*10)=0.567040592723894 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0
Fusion gene context	PubMed: ASXL2 [Title/Abstract] AND SRBD1 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ASXL2 [Title/Abstract] AND SRBD1 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ASXL2(26101035)-SRBD1(45715470), # samples:3
Anticipated loss of major functional domain due to fusion event.	ASXL2-SRBD1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ASXL2-SRBD1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ASXL2-SRBD1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ASXL2-SRBD1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ASXL2-SRBD1 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. ASXL2-SRBD1 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF. ASXL2-SRBD1 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. ASXL2-SRBD1 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	ASXL2	GO:0035360	positive regulation of peroxisome proliferator activated receptor signaling pathway	21047783
Hgene	ASXL2	GO:0045600	positive regulation of fat cell differentiation	21047783
Hgene	ASXL2	GO:0045944	positive regulation of transcription by RNA polymerase II	21047783

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:26101035/chr2:45715470)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ASXL2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across SRBD1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000435504	ASXL2	chr2	26101035	-	ENST00000263736	SRBD1	chr2	45647033	-	1920	351	153	1289	378
ENST00000435504	ASXL2	chr2	26101035	-	ENST00000535761	SRBD1	chr2	45647033	-	1507	351	153	1289	378

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000435504	ENST00000263736	ASXL2	chr2	26101035	-	SRBD1	chr2	45647033	-	0.00052036	0.9994797
ENST00000435504	ENST00000535761	ASXL2	chr2	26101035	-	SRBD1	chr2	45647033	-	0.001283905	0.9987161

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ASXL2-SRBD1

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ASXL2	chr2	26101035	SRBD1	chr2	45647033	351	66	RKKGRTWAEAAKTHDVSQTLLKATLD

Top

Potential FusionNeoAntigen Information of ASXL2-SRBD1 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ASXL2-SRBD1_26101035_45647033.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:06	THDVSQTL	0.9997	0.7765	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:01	THDVSQTL	0.9997	0.8502	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:02	THDVSQTL	0.9995	0.9438	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:01	THDVSQTL	0.9994	0.9372	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:13	THDVSQTL	0.9993	0.9107	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B15:37	THDVSQTL	0.9984	0.5193	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B14:02	THDVSQTL	0.9934	0.7522	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B14:01	THDVSQTL	0.9934	0.7522	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B15:18	THDVSQTL	0.8927	0.5932	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B45:01	AEAAKTHDV	0.9984	0.8494	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:01	THDVSQTLL	0.9977	0.8115	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:01	THDVSQTLL	0.9976	0.9207	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:02	THDVSQTLL	0.9975	0.9307	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B50:02	AEAAKTHDV	0.9972	0.5947	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:13	THDVSQTLL	0.9966	0.8669	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B15:17	KTHDVSQTL	0.9965	0.8912	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B15:16	KTHDVSQTL	0.9959	0.8002	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B57:01	KTHDVSQTL	0.9939	0.9634	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B58:01	KTHDVSQTL	0.9923	0.9162	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B58:02	KTHDVSQTL	0.9909	0.8993	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B57:03	KTHDVSQTL	0.9906	0.9769	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:06	THDVSQTLL	0.9879	0.7233	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A30:08	KTHDVSQTL	0.9833	0.7542	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A32:13	KTHDVSQTL	0.8786	0.9224	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B14:01	THDVSQTLL	0.8645	0.6622	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B14:02	THDVSQTLL	0.8645	0.6622	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B44:05	AEAAKTHDV	0.7849	0.5752	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A02:21	KTHDVSQTL	0.7466	0.5794	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B41:01	AEAAKTHDV	0.3905	0.8942	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B13:02	KTHDVSQTL	0.3041	0.5265	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B50:01	AEAAKTHDV	0.1917	0.8101	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B13:01	KTHDVSQTL	0.1638	0.9735	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B52:01	KTHDVSQTL	0.1326	0.8432	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:13	AEAAKTHDV	0.0277	0.8764	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B15:17	KTHDVSQTLL	0.9956	0.8252	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B15:16	KTHDVSQTLL	0.9955	0.6447	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B57:03	KTHDVSQTLL	0.9945	0.9691	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A30:08	KTHDVSQTLL	0.9877	0.6973	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B48:01	AKTHDVSQTL	0.8811	0.62	10	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A32:13	KTHDVSQTLL	0.8561	0.9002	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B07:10	AKTHDVSQTL	0.7103	0.5248	10	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:02	KTHDVSQTLL	0.4641	0.9409	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:01	KTHDVSQTLL	0.4636	0.9364	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A30:08	KTHDVSQTLLK	0.9993	0.5475	11	22
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:01	AKTHDVSQTLL	0.9209	0.9434	10	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:02	AKTHDVSQTLL	0.9154	0.9465	10	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:07	THDVSQTL	0.9999	0.9483	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:10	THDVSQTL	0.9999	0.9479	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:09	THDVSQTL	0.9997	0.6806	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:12	THDVSQTL	0.9996	0.8571	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:05	THDVSQTL	0.9993	0.8415	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:13	THDVSQTL	0.9642	0.9082	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:29	THDVSQTL	0.9584	0.9182	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B14:03	THDVSQTL	0.9433	0.7954	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:08	THDVSQTL	0.895	0.8512	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:14	THDVSQTL	0.8368	0.9536	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C15:04	KTHDVSQTL	0.9997	0.892	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C05:09	THDVSQTLL	0.9996	0.9421	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:10	THDVSQTLL	0.9995	0.9273	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C15:06	KTHDVSQTL	0.9994	0.9017	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:07	THDVSQTLL	0.9994	0.9314	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C08:15	THDVSQTLL	0.9991	0.9727	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:19	KTHDVSQTL	0.9989	0.9825	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:07	KTHDVSQTL	0.9988	0.9439	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:08	KTHDVSQTL	0.9987	0.909	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:06	KTHDVSQTL	0.9983	0.8752	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C05:09	KTHDVSQTL	0.9983	0.8954	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B40:06	AEAAKTHDV	0.9979	0.7292	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:05	THDVSQTLL	0.9974	0.8003	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:12	THDVSQTLL	0.9974	0.8197	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:14	KTHDVSQTL	0.9972	0.9075	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:09	THDVSQTLL	0.9958	0.5536	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:19	KTHDVSQTL	0.9951	0.7249	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C08:04	KTHDVSQTL	0.9948	0.937	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C08:13	KTHDVSQTL	0.9948	0.937	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:05	KTHDVSQTL	0.993	0.9371	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C01:17	KTHDVSQTL	0.9929	0.9297	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C06:03	KTHDVSQTL	0.9906	0.9794	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:29	KTHDVSQTL	0.9904	0.9015	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C12:04	KTHDVSQTL	0.9901	0.9756	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:27	KTHDVSQTL	0.9895	0.919	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:14	KTHDVSQTL	0.9893	0.9669	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C12:12	KTHDVSQTL	0.9878	0.9034	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:95	KTHDVSQTL	0.9874	0.6277	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:13	KTHDVSQTL	0.9868	0.8808	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C12:16	KTHDVSQTL	0.9643	0.9266	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B44:10	AEAAKTHDV	0.9431	0.7122	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B15:04	KTHDVSQTL	0.9285	0.8507	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C08:03	KTHDVSQTL	0.9257	0.9741	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C02:06	KTHDVSQTL	0.9076	0.9213	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:08	KTHDVSQTL	0.8489	0.7826	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B44:09	AEAAKTHDV	0.8315	0.5827	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C01:30	KTHDVSQTL	0.8228	0.9315	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:08	THDVSQTLL	0.8108	0.8249	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B14:03	THDVSQTLL	0.6356	0.7422	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:13	THDVSQTLL	0.5588	0.8829	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:29	THDVSQTLL	0.5493	0.903	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:67	THDVSQTLL	0.521	0.8957	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:80	THDVSQTLL	0.521	0.8957	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:46	THDVSQTLL	0.4438	0.8265	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:14	THDVSQTLL	0.4008	0.9391	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:08	AEAAKTHDV	0.3324	0.8978	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C05:09	KTHDVSQTLL	0.9996	0.8875	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C15:06	KTHDVSQTLL	0.9995	0.8823	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:05	KTHDVSQTLL	0.4651	0.7974	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:05	AKTHDVSQTLL	0.8962	0.796	10	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C18:01	THDVSQTL	0.9999	0.942	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:01	THDVSQTL	0.9999	0.9483	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:31	THDVSQTL	0.9997	0.8509	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:02	THDVSQTL	0.9996	0.9066	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:05	THDVSQTL	0.9994	0.9372	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:11	THDVSQTL	0.9753	0.751	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:04	THDVSQTL	0.9731	0.9442	12	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C15:09	KTHDVSQTL	0.9997	0.892	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C05:01	THDVSQTLL	0.9996	0.9421	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C15:02	KTHDVSQTL	0.9995	0.8497	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:03	THDVSQTLL	0.9995	0.9402	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C15:05	KTHDVSQTL	0.9994	0.8554	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:01	THDVSQTLL	0.9994	0.9314	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C08:02	THDVSQTLL	0.9991	0.9727	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C18:01	THDVSQTLL	0.9988	0.9233	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:17	KTHDVSQTL	0.9987	0.9377	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C05:01	KTHDVSQTL	0.9983	0.8954	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C06:06	KTHDVSQTL	0.9982	0.9763	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:04	KTHDVSQTL	0.9982	0.9815	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:03	KTHDVSQTL	0.9982	0.9815	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:03	KTHDVSQTL	0.9982	0.8813	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:04	KTHDVSQTL	0.9981	0.8909	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:02	THDVSQTLL	0.998	0.8625	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C18:01	KTHDVSQTL	0.9978	0.8685	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:31	THDVSQTLL	0.9976	0.8127	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:05	THDVSQTLL	0.9976	0.9207	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:05	KTHDVSQTL	0.9975	0.8645	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:67	KTHDVSQTL	0.9973	0.9721	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C16:04	KTHDVSQTL	0.9972	0.9484	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C16:01	KTHDVSQTL	0.9969	0.9571	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C16:02	KTHDVSQTL	0.9964	0.9821	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:22	KTHDVSQTL	0.9963	0.6378	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B57:04	KTHDVSQTL	0.9949	0.6868	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B58:06	KTHDVSQTL	0.9948	0.8031	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:02	KTHDVSQTL	0.9945	0.9435	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C01:03	KTHDVSQTL	0.9945	0.9344	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B57:02	KTHDVSQTL	0.994	0.8493	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B57:10	KTHDVSQTL	0.9939	0.9634	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C06:02	KTHDVSQTL	0.9933	0.9755	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C06:17	KTHDVSQTL	0.9933	0.9755	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C01:02	KTHDVSQTL	0.993	0.9247	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C12:03	KTHDVSQTL	0.9925	0.9549	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:01	KTHDVSQTL	0.9923	0.6217	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A32:01	KTHDVSQTL	0.9922	0.9245	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:17	KTHDVSQTL	0.9921	0.9414	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:06	KTHDVSQTL	0.9872	0.9806	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:04	KTHDVSQTL	0.9871	0.9412	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B40:04	AEAAKTHDV	0.9849	0.8184	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A30:01	KTHDVSQTL	0.9842	0.8696	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B15:24	KTHDVSQTL	0.9794	0.8726	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C12:02	KTHDVSQTL	0.9624	0.9297	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B15:73	KTHDVSQTL	0.9372	0.785	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C08:01	KTHDVSQTL	0.9257	0.9741	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B15:30	KTHDVSQTL	0.9186	0.762	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C03:67	THDVSQTLL	0.8746	0.9313	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:11	THDVSQTLL	0.827	0.7158	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C02:02	KTHDVSQTL	0.7998	0.9515	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C02:10	KTHDVSQTL	0.7998	0.9515	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C06:06	THDVSQTLL	0.7882	0.9843	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:02	KTHDVSQTL	0.767	0.8981	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C06:08	KTHDVSQTL	0.7633	0.9679	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A02:06	KTHDVSQTL	0.7466	0.5794	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B35:13	KTHDVSQTL	0.7459	0.8632	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B07:13	KTHDVSQTL	0.6877	0.7703	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C04:04	THDVSQTLL	0.6568	0.899	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C17:01	KTHDVSQTL	0.592	0.913	11	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:17	THDVSQTLL	0.5315	0.9227	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:02	THDVSQTLL	0.521	0.8957	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C07:04	THDVSQTLL	0.4924	0.9382	12	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B41:03	AEAAKTHDV	0.4728	0.7088	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B50:04	AEAAKTHDV	0.1917	0.8101	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B50:05	AEAAKTHDV	0.1917	0.8101	7	16
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C05:01	KTHDVSQTLL	0.9996	0.8875	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C15:02	KTHDVSQTLL	0.9995	0.8345	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-C15:05	KTHDVSQTLL	0.9995	0.837	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B57:02	KTHDVSQTLL	0.9962	0.8175	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:02	AKTHDVSQTL	0.9929	0.9055	10	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A32:01	KTHDVSQTLL	0.9874	0.9059	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:11	THDVSQTLLK	0.7247	0.6036	12	22
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:11	KTHDVSQTLL	0.7235	0.6931	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:05	KTHDVSQTLL	0.4636	0.9364	11	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-A30:01	KTHDVSQTLLK	0.9993	0.7532	11	22
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B39:11	AKTHDVSQTLL	0.9962	0.7732	10	21
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B35:13	AAKTHDVSQTL	0.9624	0.8149	9	20
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	HLA-B38:05	AKTHDVSQTLL	0.9209	0.9434	10	21

Top

Potential FusionNeoAntigen Information of ASXL2-SRBD1 in HLA II

ASXL2-SRBD1_26101035_45647033.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0801	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0801	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0805	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0805	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0816	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0816	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0818	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0826	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0826	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0829	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0829	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0839	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0839	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0840	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-0840	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1303	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1303	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-13101	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-13101	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1310	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1310	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1312	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1312	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1313	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1321	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1321	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1349	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1349	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1355	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1355	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1366	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1366	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1388	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1388	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1390	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1390	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1395	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1395	KGRTWAEAAKTHDVS	2	17
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1422	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1425	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1469	GRTWAEAAKTHDVSQ	3	18
ASXL2-SRBD1	chr2	26101035	chr2	45647033	351	DRB1-1485	GRTWAEAAKTHDVSQ	3	18

Top

Fusion breakpoint peptide structures of ASXL2-SRBD1

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
10415	WAEAAKTHDVSQTL	ASXL2	SRBD1	chr2	26101035	chr2	45647033	351

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ASXL2-SRBD1

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	10415	WAEAAKTHDVSQTL	-7.9962	-8.1096
HLA-B14:02	3BVN	10415	WAEAAKTHDVSQTL	-5.70842	-6.74372
HLA-B52:01	3W39	10415	WAEAAKTHDVSQTL	-6.83737	-6.95077
HLA-B52:01	3W39	10415	WAEAAKTHDVSQTL	-4.4836	-5.5189
HLA-A11:01	4UQ2	10415	WAEAAKTHDVSQTL	-10.0067	-10.1201
HLA-A11:01	4UQ2	10415	WAEAAKTHDVSQTL	-9.03915	-10.0745
HLA-A24:02	5HGA	10415	WAEAAKTHDVSQTL	-6.56204	-6.67544
HLA-A24:02	5HGA	10415	WAEAAKTHDVSQTL	-5.42271	-6.45801
HLA-B44:05	3DX8	10415	WAEAAKTHDVSQTL	-7.85648	-8.89178
HLA-B44:05	3DX8	10415	WAEAAKTHDVSQTL	-5.3978	-5.5112
HLA-B35:01	1A1N	10415	WAEAAKTHDVSQTL	-6.27422	-6.38762
HLA-B35:01	1A1N	10415	WAEAAKTHDVSQTL	-5.27424	-6.30954
HLA-A02:01	6TDR	10415	WAEAAKTHDVSQTL	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ASXL2-SRBD1

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ASXL2-SRBD1	chr2	26101035	chr2	45647033	10	20	AKTHDVSQTL	GCCAAGACGCATGACGTATCCCAGACTTTA
ASXL2-SRBD1	chr2	26101035	chr2	45647033	10	21	AKTHDVSQTLL	GCCAAGACGCATGACGTATCCCAGACTTTACTC
ASXL2-SRBD1	chr2	26101035	chr2	45647033	11	20	KTHDVSQTL	AAGACGCATGACGTATCCCAGACTTTA
ASXL2-SRBD1	chr2	26101035	chr2	45647033	11	21	KTHDVSQTLL	AAGACGCATGACGTATCCCAGACTTTACTC
ASXL2-SRBD1	chr2	26101035	chr2	45647033	11	22	KTHDVSQTLLK	AAGACGCATGACGTATCCCAGACTTTACTCAAG
ASXL2-SRBD1	chr2	26101035	chr2	45647033	12	20	THDVSQTL	ACGCATGACGTATCCCAGACTTTA
ASXL2-SRBD1	chr2	26101035	chr2	45647033	12	21	THDVSQTLL	ACGCATGACGTATCCCAGACTTTACTC
ASXL2-SRBD1	chr2	26101035	chr2	45647033	12	22	THDVSQTLLK	ACGCATGACGTATCCCAGACTTTACTCAAG
ASXL2-SRBD1	chr2	26101035	chr2	45647033	7	16	AEAAKTHDV	GCGGAGGCCGCCAAGACGCATGACGTA
ASXL2-SRBD1	chr2	26101035	chr2	45647033	9	20	AAKTHDVSQTL	GCCGCCAAGACGCATGACGTATCCCAGACTTTA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
ASXL2-SRBD1	chr2	26101035	chr2	45647033	2	17	KGRTWAEAAKTHDVS	AAGGGCAGGACCTGGGCGGAGGCCGCCAAGACGCATGACGTATCC
ASXL2-SRBD1	chr2	26101035	chr2	45647033	3	18	GRTWAEAAKTHDVSQ	GGCAGGACCTGGGCGGAGGCCGCCAAGACGCATGACGTATCCCAG

Top

Information of the samples that have these potential fusion neoantigens of ASXL2-SRBD1

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
LUAD	ASXL2-SRBD1	chr2	26101035	ENST00000435504	chr2	45647033	ENST00000263736	TCGA-44-7670-01A

Top

Potential target of CAR-T therapy development for ASXL2-SRBD1

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to ASXL2-SRBD1

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ASXL2-SRBD1

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	ASXL2	C0005684	Malignant neoplasm of urinary bladder	1	CTD_human
Hgene	ASXL2	C0005695	Bladder Neoplasm	1	CTD_human
Hgene	ASXL2	C0023467	Leukemia, Myelocytic, Acute	1	CTD_human
Hgene	ASXL2	C0026998	Acute Myeloid Leukemia, M1	1	CTD_human
Hgene	ASXL2	C1879321	Acute Myeloid Leukemia (AML-M2)	1	CTD_human
Hgene	ASXL2	C4310672	SHASHI-PENA SYNDROME	1	GENOMICS_ENGLAND

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)